Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

12,957 total articles

Relmada Therapeutics Joins Russell 2000® and Russell 3000® Indexes

Relmada Therapeutics Joins Russell 2000® and Russell 3000® Indexes

Relmada Therapeutics, a clinical-stage biotech company focused on oncology and CNS therapies, announced it has been added to the Russell 2000 and Russell 3000 Indexes following the June 2026 reconstitution. This inclusion reflects the company's progress, supported by robust clinical data for its lead candidate NDV-01 and a strong financial position…

Agios to Host Second Quarter 2026 Financial Results Conference Call and Webcast on July 30 at 8:00 a.m. ET

Agios to Host Second Quarter 2026 Financial Results Conference Call and Webcast on July 30 at 8:00 a.m. ET

Agios Pharmaceuticals, a commercial-stage biopharmaceutical company specializing in rare diseases, will hold a conference call and webcast on July 30, 2026, at 8:00 a.m. ET to report its second quarter 2026 financial results and business highlights. The event will be accessible via the company's investor website, with a replay available afterward.

Satellos Receives FDA Fast Track Designation for SAT-3247 for the Treatment of Duchenne Muscular Dystrophy

Satellos Receives FDA Fast Track Designation for SAT-3247 for the Treatment of Duchenne Muscular Dystrophy

Satellos Bioscience announced that the FDA has granted Fast Track designation to its investigational drug, SAT-3247, for the treatment of Duchenne Muscular Dystrophy (DMD). This designation, along with previous Orphan Drug and Rare Pediatric Disease recognitions, is intended to expedite the development and review process of SAT-3247. The company is…

Dianthus Therapeutics Announces Initiation of Phase 3 Emerge Trial of Claseprubart in Generalized Myasthenia Gravis

Dianthus Therapeutics Announces Initiation of Phase 3 Emerge Trial of Claseprubart in Generalized Myasthenia Gravis

Dianthus Therapeutics announced the initiation of the global Phase 3 EMERGE trial testing claseprubart, an investigational monoclonal antibody targeting the classical complement pathway, in acetylcholine receptor antibody positive generalized Myasthenia Gravis patients. This follows promising Phase 2 results showing rapid and significant symptom im…

BioCryst Sharpens Scientific Focus on External Innovation with Wind Down of Internal Discovery Programs and Closure of Birmingham Research Facility

BioCryst Sharpens Scientific Focus on External Innovation with Wind Down of Internal Discovery Programs and Closure of Birmingham Research Facility

BioCryst Pharmaceuticals announces a strategic shift from internal discovery programs to external innovation partnerships to accelerate its rare disease pipeline growth. The company will discontinue internal discovery efforts and close its Birmingham research facility by the end of 2026. BioCryst has completed enrollment in the pivotal Phase 3 stud…

Biogen to Highlight Breadth of Alzheimer’s Disease Portfolio at AAIC 2026, Including Phase 2 CELIA Data for Diranersen

Biogen to Highlight Breadth of Alzheimer’s Disease Portfolio at AAIC 2026, Including Phase 2 CELIA Data for Diranersen

Biogen announced it will showcase new data on its Alzheimer's disease portfolio at the AAIC 2026 conference, including Phase 2 results from the CELIA study evaluating diranersen, an investigational tau-targeting antisense oligonucleotide, and updated analyses on lecanemab, addressing amyloid and tau pathologies. The data underscore Biogen's leaders…

Golar LNG Limited

Golar LNG Limited

Golar LNG Limited announced that it will release its second quarter 2026 financial results before market open on Thursday, August 13, 2026. A webcast presentation will be held at 8:00 am Eastern Time followed by a Q&A session accessible to sell-side analysts. The company provides detailed instructions for accessing the live webcast and teleconferen…

ScottsMiracle-Gro Announces Strategic Leadership Succession

ScottsMiracle-Gro Announces Strategic Leadership Succession

The Scotts Miracle-Gro Company announced Nate Baxter as its new president and CEO, succeeding long-time leader Jim Hagedorn. Baxter, instrumental in crafting the company’s multi-year growth strategy SMG 2.0, aims to drive operational excellence and innovation. The company reaffirmed its fiscal 2026 guidance emphasizing steady sales growth, margin t…

Ring Energy Joins Russell 3000® Index

Ring Energy Joins Russell 3000® Index

Ring Energy, Inc., a Texas-based independent oil and natural gas exploration and production company, announced its inclusion in the Russell 3000® Index effective June 29, 2026. This inclusion reflects Ring Energy's substantial market capitalization, leading to increased visibility among institutional investors and broader ownership of its shares. T…

FTAI Infrastructure Announces Acquisition of Tidewater Logistics

FTAI Infrastructure Announces Acquisition of Tidewater Logistics

FTAI Infrastructure Inc. has acquired Tidewater Logistics, a barge and rail transloading company operating in Ohio, West Virginia, and Texas, for approximately $45 million. The acquisition is funded through an upsized term loan and is expected to generate $9 million in Adjusted EBITDA over the next year. The deal complements FIP's existing Wheeling…

Larimar Therapeutics Reports Positive Open Label Data and Submission of First Module of Rolling BLA for Accelerated Approval of Nomlabofusp for Friedreich’s Ataxia

Larimar Therapeutics Reports Positive Open Label Data and Submission of First Module of Rolling BLA for Accelerated Approval of Nomlabofusp for Friedreich’s Ataxia

Larimar Therapeutics reported encouraging long-term data from its open-label study evaluating nomlabofusp in Friedreich's Ataxia patients, showing sustained increases in skin frataxin levels and associated clinical improvements. The company submitted the first module of a rolling Biologics License Application (BLA) to the FDA based on positive FDA …

Nova Minerals Announces Korbel Floatation Test-work Produces High-Grade Gold Concentrate up to 26.7 g/t Au with Consistent Recoveries Exceeding 95%

Nova Minerals Announces Korbel Floatation Test-work Produces High-Grade Gold Concentrate up to 26.7 g/t Au with Consistent Recoveries Exceeding 95%

Nova Minerals Corp announced successful bench-scale flotation test results on low-grade Korbel ore showing >95% gold recovery and producing high-grade concentrate up to 26.7 g/t Au. The results indicate potential to simplify processing, reduce capital and operating costs, and enhance the feasibility study outcomes for the Estelle Gold Project in Al…

Diana Shipping Inc. Announces Extension of Tender Offer for All Outstanding Shares of Genco Shipping & Trading

Diana Shipping Inc. Announces Extension of Tender Offer for All Outstanding Shares of Genco Shipping & Trading

Diana Shipping Inc. announced an extension of its tender offer to acquire all outstanding shares of Genco Shipping & Trading that it does not already own. The offer values Genco shares at $27.34 each, consisting of cash and Diana shares, representing a significant premium over Genco's current market price. Over 28% of Genco's non-Diana shares have …

OwlTing Group (NASDAQ: OWLS) and Saber Money Open Settlement into India's US$860 Billion Export Economy

OwlTing Group (NASDAQ: OWLS) and Saber Money Open Settlement into India's US$860 Billion Export Economy

OwlTing Group (NASDAQ: OWLS) has integrated Saber Money’s cross-border digital currency payment infrastructure into its OwlPay Harbor platform, enabling near real-time settlement into India in Indian rupees and expanding pay-in and payout capabilities into the Eurozone and UK. This partnership allows OwlTing to tap into India’s growing $860 billion…

MEXCO ENERGY CORPORATION REPORTS FINANCIAL RESULTS FOR FISCAL 2026

MEXCO ENERGY CORPORATION REPORTS FINANCIAL RESULTS FOR FISCAL 2026

Mexco Energy Corporation reported a 24% decrease in net income for fiscal 2026 compared to the previous year, driven by lower oil prices and reduced oil production despite increased natural gas prices and production. The company invested $1.25 million in drilling activities, focusing mainly on the Delaware Basin, and maintains strong liquidity with…

Comstock Metals Advances Industry-Scale Facility Commissioning

Comstock Metals Advances Industry-Scale Facility Commissioning

Comstock Inc. and its subsidiary Comstock Metals announced significant progress in commissioning their industry-scale solar panel recycling facility. Key precision equipment units including robotic loading arms, the Eddy glass-upgrading system, and washing system have been assembled, tested, and are now being integrated. The facility is expected to…

Creative Realities Announces Proposed Public Offering

Creative Realities Announces Proposed Public Offering

Creative Realities, Inc., a digital signage and AdTech solutions provider, announced the commencement of an underwritten offering of its common stock and pre-funded warrants. The company intends to use the net proceeds for working capital, general corporate purposes, debt paydown, and potential acquisitions. The offering includes a 30-day option fo…

Global Net Lease Closes $74 Million of Dispositions Since First Quarter 2026, Achieving a 7.2% Cash Cap Rate on Occupied Sales

Global Net Lease Closes $74 Million of Dispositions Since First Quarter 2026, Achieving a 7.2% Cash Cap Rate on Occupied Sales

Global Net Lease, Inc. announced it has sold $74 million of assets since Q1 2026, focusing on reducing office exposure by disposing $66 million in occupied properties, mostly office assets, at a 7.2% cash cap rate. Concurrently, GNL plans to acquire a 100,000-square-foot industrial property and is on track to complete a $535 million acquisition of …

Zymeworks to Acquire Theravance Biopharma, Inc.

Zymeworks to Acquire Theravance Biopharma, Inc.

Zymeworks Inc. has entered into a definitive agreement to acquire Theravance Biopharma, expanding its portfolio with YUPELRI®, the first nebulized long-acting muscarinic antagonist approved for COPD maintenance treatment. The $929 million cash transaction is financed primarily through a non-recourse note and cash reserves, expected to be accretive …

McEwen Inc. Joins Russell 2000® Index

McEwen Inc. Joins Russell 2000® Index

McEwen Inc., a diversified gold, silver, and copper mining company, has been added to the Russell 2000® Index as part of the June 2026 Russell Reconstitution. This inclusion is expected to increase the company's visibility among institutional investors and index funds. McEwen is focused on expanding its precious metals production and advancing its …